secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001447362-24-000121
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M
--------------------------------------------------------------------------------

- Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
- Total test reports 25,102 (+49% YoY); TissueCypher +230%, DecisionDx-SCC +60%.
- Raises FY2024 revenue guidance to $275-300M from prior $255-265M.
- Adjusted EBITDA $21.5M vs ($5.3M) in Q2 2023; gross margin 81%.
- Cash and investments $259.7M; net cash from operations $24.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000121/0001447362-24-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000121/cstl-20240805.htm
  HTML page:      https://secwatch.observer/filing/0001447362-24-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer